IP Library Granted Patent US 9,587,241
Granted Patent B2
US 9,587,241 · App. 14/033,664 · Granted Mar 7, 2017

Biosynthesis of human milk oligosaccharides in engineered bacteria

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,587,241
App. No.
14/033,664
Granted
Mar 7, 2017
Kind
B2
Abstract

The invention provides compositions and methods for engineering bacteria to produce fucosylated oligosaccharides, and the use thereof in the prevention or treatment of infection.

Claims (34)

1. An isolated E. coli bacterium comprising

(i) a deletion or functional inactivation of an endogenous β-galactosidase gene;

(ii) an exogenous functional β-galactosidase gene comprising a detectable level of β-galactosidase activity that is reduced compared to that of a wild-type E. coli bacterium, wherein the level of β-galactosidase activity comprises between 0.05 and 200 units;

(iii) an inactivating mutation in a colanic acid synthesis gene; and

(iv) an exogenous lactose-accepting fucosyltransferase gene.

2. The bacterium of claim 1 , wherein said colanic acid synthesis gene comprises an E. coli wcaJ, wzxC, wcaD, wza, wzb, or wzc gene.

3. The bacterium of claim 2 , wherein said colanic acid synthesis gene comprises a wcaJ gene.

4. The bacterium of claim 1 , comprising an increased intracellular guanosine diphosphate (GDP)-fucose level, wherein the increased intracellular GDP-fucose level is at least 10% more than the level of GDP-fucose in a wild-type bacterium.

5. The bacterium of claim 1 , wherein said exogenous lactose-accepting fucosyltransferase gene encodes α(1,2) fucosyltransferase and/or α(1,3) fucosyltransferase.

6. The bacterium of claim 5 , wherein said α(1,2) fucosyltransferase gene comprises a Bacteroides fragilis wcfW gene.

7. The bacterium of claim 5 , wherein said α(1,3) fucosyltransferase gene comprises a Helicobacter pylori 26695 futA gene.

8. The bacterium of claim 1 , wherein said exogenous functional β-galactosidase gene comprises an E. coli lacZ gene.

9. The bacterium of claim 8 , wherein the lacZ gene is inserted into an endogenous lon gene.

10. The bacterium of claim 1 , further comprising a functional lactose permease gene.

11. The bacterium of claim 10 , wherein said lactose permease gene is an endogenous lactose permease gene.

12. The bacterium of claim 10 , wherein said lactose permease gene comprises an E. coli lacY gene.

13. The bacterium of claim 1 , further comprising an exogenous E. coli rcsA or E. coli rcsB gene.

14. The bacterium of claim 1 , further comprising an inactivating mutation in a lacA gene.

15. The bacterium of claim 1 , further comprising an exogenous sialyltransferase gene.

16. The bacterium of claim 15 , wherein said exogenous sialyltransferase gene encodes an α(2,3)sialyl transferase.

17. The bacterium of claim 1 , further comprising a deficient sialic acid catabolic pathway comprising a null mutation in an endogenous N-acetylneuraminate lyase gene or a null mutation in an endogenous N-acetylmannosamine kinase gene.

18. The bacterium of claim 1 , wherein the level of β-galactosidase activity comprises between 0.05 and 5 units.

19. The bacterium of claim 1 , further comprising an inactivating mutation in a ion gene.

20. The bacterium of claim 1 , comprising an increased intracellular lactose level, wherein the increased intracellular lactose level is at least 10% more than the level in a wild-type bacterium.

21. The bacterium of claim 1 , wherein said exogenous functional β-galactosidase gene is an E. coli lacZ gene lacking an operably linked promoter, and said colanic acid synthesis gene comprises an E. coli wcaJ, wzxC, wcaD, wza, wzb, or wzc gene.

22. The bacterium of claim 1 , comprising the genotype of

(a) ampC::(P trpB λcI + ), P lacI q (ΔlacI-lacZ)lacY + , ΔwcaJ, thyA::Tn10, Δlon::(kan, lacZ + ); or

(b) ampC::(P trpB λcI + ), P lacI q (ΔlacI-lacZ)lacY + , ΔwcaJ, thyA::Tn10, Δlon::(kan, lacZ + ) ΔlacA.

23. The bacterium of claim 1 , wherein said exogenous functional β-galactosidase gene is inserted into an endogenous gene.

24. The bacterium of claim 1 , wherein said exogenous functional β-galactosidase gene comprises a recombinant β-galactosidase gene engineered to produce a detectable level of β-galactosidase activity that is reduced compared to the level of β-galactosidase activity in a wild-type E. coli bacterium.

25. The bacterium of claim 24 , wherein the level of β-galactosidase activity comprises between 0.05 and 5 units.

26. The bacterium of claim 1 , wherein the level of β-galactosidase activity comprises between 0.05 and 4 units.

27. The bacterium of claim 1 , wherein the level of β-galactosidase activity comprises between 0.05 and 3 units.

28. The bacterium of claim 1 , wherein the level of β-galactosidase activity comprises between 0.05 and 2 units.

Assignments (4)
RELEASE OF SECURITY INTEREST Recorded Jun 6, 2025
From: MINTZ LEVIN COHN FERRIS GLOVSKY AND POPEO, P.C.
To: GLYCOSYN, LLC
Reel/Frame 071338/0562 →
SECURITY INTEREST Recorded May 12, 2022
From: GLYCOSYN LLC; GLYCOSYN, INC.
To: GINKGO BIOWORKS, INC.
Reel/Frame 060052/0477 →
SECURITY INTEREST Recorded Feb 4, 2021
From: GLYCOSYN LLC
To: MINTZ, LEVIN, COHN, FERRIS, GLOVSKY AND POPEO, P.C.
Reel/Frame 055148/0944 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 10, 2014
From: MERIGHI, MASSIMO; MCCOY, JOHN M.; HEIDTMAN, MATTHEW IAN
To: GLYCOSYN LLC.
Reel/Frame 031942/0721 →